Is NCT06667700 recruiting in Oxnard, CA?

Yes, NCT06667700 is currently recruiting participants at its Oxnard, CA location. This covid-19 clinical trial is actively enrolling qualified participants.

How do I join the covid-19 clinical trial in Oxnard?

To join this clinical trial in Oxnard, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Oxnard clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

COVID-19 Clinical Trial in Oxnard, CA

About This COVID-19 Study in Oxnard

Researchers are looking for other ways to prevent severe illness from COVID-19. COVID-19 is a virus that most often causes mild flu or cold-like symptoms. However, people with certain health conditions or other factors have a high risk (chance) of getting severely ill from COVID-19, which can require a hospital stay or lead to death. Some people who are high risk for severe illness may be unable to take certain treatments for COVID-19 because they are not available to them, or they take other me

Sponsor: Merck Sharp & Dohme LLC

Who Can Participate

Inclusion Criteria

The main inclusion criteria include but are not limited to the following:

Is an individual of any sex/gender, ≥18 years of age

Has documentation of SARS-CoV-2 infection with sample collection ≤4 days prior to randomization

Has initial onset of signs/symptoms attributable to COVID-19 for ≤4 days prior to the day of randomization and ≥2 of the following signs/symptoms attributable to COVID-19 on the day of randomization: cough, sore throat, nasal congestion, shortness of breath or difficulty breathing with exertion, muscle or body aches, fatigue, fever \>38.0°C or chills, nausea or vomiting or diarrhea, change in sense of smell or change in sense of taste, or headache

Has ≥1 of the following characteristics or medical conditions associated with the highest risk of severe illness from COVID-19:

Advanced age of ≥75 years of age

Immunocompromised

Neurocognitive or physical disability

Has ≥3 characteristics or medical conditions which increase the risk of severe illness due to COVID-19 (e.g., chronic lung disease, obesity with body mass index (BMI) ≥35, diabetes)

Is unable or unwilling to receive treatment with nirmatrelvir/ritonavir (NMV/r) due to 1 or more of the following:

Is receiving drug(s) highly dependent on cytochrome P450 3A (CYP3A) for clearance and for which elevated concentrations are associated with serious and/or life-threatening consequences or drug(s) with a clinically significant drug-drug interaction for which co-administration is not possible

Is receiving potent CYP3A inducers where significantly reduced nirmatrelvir or ritonavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance

Has severe hepatic impairment

Has experienced prior adverse reactions or hepatotoxicity to NMV/r that would preclude future use

Has known or suspected NMV/r resistance

Has uncontrolled HIV infection

NMV/r is not approved/authorized in the participant's country or it is not accessible to participant (e.g., drug shortage)

Is unwilling to receive treatment with NMV/r Inclusion note: Participants may receive remdesivir as standard of care in addition to molnupiravir or placebo. If remdesivir is available and clinically appropriate per local clinical practice, investigators will aim to ensure that those who are most vulnerable to severe COVID-19 receive timely access to remdesivir as standard of care on this study.

Exclusion Criteria

The main exclusion criteria include but are not limited to the following:

Is currently hospitalized or is expected to need hospitalization for COVID-19 imminently

Has received or plans to receive SARS-CoV-2 directed oral antivirals or monoclonal antibodies for current episode of COVID-19 (other than study intervention and, if applicable, remdesivir as standard of care)

Has ≥1 of the following signs/symptoms that are attributable to severe or critical COVID-19:

Shortness of breath at rest

Respiratory rate ≥30 breaths per minute

Heart rate ≥125 beats per minute

Peripheral oxygen saturation (SpO2) ≤93% on room air or on supplemental oxygen for a reason other than COVID-19 which has not increased since onset of COVID-19 signs/symptoms

New or increasing need for supplemental oxygen: receiving \>4 liters/minute supplemental oxygen due to COVID-19 OR on supplemental oxygen for a reason other than COVID-19 which has increased due to COVID-19

Has received a COVID-19 vaccine within 30 days prior to randomization

Has a history of confirmed influenza, respiratory syncytial virus (RSV), or SARS-CoV-2 infection (with or without symptoms; excluding current infection) within 30 days prior to randomization

Has known or suspected hypersensitivity to active or inactive ingredients of molnupiravir

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Oxnard?

Yes, this clinical trial (NCT06667700) has an active research site in Oxnard, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

COVID-19 Treatment Options in Oxnard, CA

If you're searching for covid-19 treatment options in Oxnard, CA, this clinical trial (NCT06667700) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Oxnard research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced covid-19 specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all covid-19 clinical trials near you to find additional studies recruiting in your area.

COVID-19 Clinical Trial in Oxnard, CA

Expert Care in Oxnard

IRB Approved

No-Cost Care

Apply for This Oxnard Location

Why Participate?

Simple Process